FDA Postmarket Cybersecurity for Infusion & Drug Delivery
Postmarket cybersecurity for infusion & drug delivery: SBOM monitoring, vulnerability disclosure, field updates, and manufacturer-reviewed risk decisions.
Aligned to FDA's February 3, 2026 premarket cybersecurity guidance.
Postmarket cybersecurity for infusion pumps and connected drug-delivery systems starts with the deployed system, not just the submission-time SBOM. Pump firmware, management servers, and drug-library distribution need linked postmarket records. Clinical availability and hospital change control affect field remediation. For devices and submissions within Section 524B scope, the statute requires a plan to monitor, identify, and address postmarket vulnerabilities, including coordinated vulnerability disclosure procedures. FDA guidance recommendations and statutory duties are documented separately.
Blue Goat reviews the component inventory against supported field configurations, monitors vulnerability sources, and documents applicability and exploitability evidence for manufacturer review. We can set up or operate coordinated vulnerability disclosure intake and connect technical review to your change-control process. Field-update planning records affected versions, deployment constraints, recovery steps, and customer communications. The scope follows the interfaces your product actually uses.
Firmware and drug-library changes need distinct integrity checks, compatible versions, and documented deployment confirmation. Reports need to distinguish configuration access, dose-command integrity, and alarm or delivery interruption. An advisory or CVSS 4.0 score alone does not establish clinical harm. Your team supplies device-specific safety evidence and approves risk acceptance, VEX statements when used, remediation, and regulatory reporting decisions.
Layers we exercise in this engagement
The infusion / drug delivery system, from the outermost cloud and clinician surfaces down to the device itself. Highlighted layers are exercised by this fda postmarket cybersecurity.
- 01Hospital integration Tested
- 02Pump management Tested
- 03Drug-library delivery Tested
- 04Pump firmware Tested
- 05Vulnerability intake (CVD) Tested
Layers shown outermost (top) to innermost (bottom). Dashed rows are part of the surrounding system but out of scope for this view.
FDA Postmarket Cybersecurity engagement, end to end
Four phases, fixed fee, scoped to infusion / drug delivery architecture from kickoff onward.
- 01
Deployed-system scope
Confirm supported software versions, connected components, deployment constraints, and manufacturer owners.
- 02
Monitoring and technical review
Review vulnerability sources against deployed components. Record applicability and exploitability evidence for manufacturer approval.
- 03
Coordinated vulnerability disclosure
Set up or operate intake, triage, and disclosure procedures connected to your change-control process.
- 04
Field response and records
Document remediation options, update and recovery plans, affected configurations, and communications. The manufacturer approves risk, clinical, and reporting decisions.
What we see in Infusion / Drug Delivery fda postmarket cybersecurity
The patterns we hit in this segment, this service, again and again.
Deployed component inventory can be incomplete
A pump-only inventory can omit the server that distributes configuration across the fleet.
Field-update coverage can be unclear
Firmware and drug-library changes need distinct integrity checks, compatible versions, and documented deployment confirmation.
Vulnerability triage can miss the clinical context
Reports need to distinguish configuration access, dose-command integrity, and alarm or delivery interruption.
Disclosure intake can be disconnected from change control
A report can remain in a support inbox without an assigned technical owner, affected-version record, or documented manufacturer decision. We review that handoff and the evidence retained for closure.
Standard FDA Postmarket Cybersecurity deliverables
The same deliverables the parent FDA Postmarket Cybersecurity service ships with - tuned to your infusion / drug delivery architecture.
- TPLC Partnership: Annual retainer covering one product line through Total Product Lifecycle - SBOM monitoring, CISA-KEV tracking, full CVD process operation, quarterly penetration tests, and ongoing FDA/EU regulatory updates. One predictable fee, one accountable team, zero gaps between cleared release and end-of-support.
- SBOM monitoring: Section 524B requires manufacturers to maintain and update SBOMs continuously. We track every component for newly disclosed CVEs and flag them before they become reportable vulnerabilities.
- CVD program (Coordinated Vulnerability Disclosure): We manage the full CVD process - researcher intake, triage, fix timeline, and FDA notification - so your team doesn't face a public disclosure event without a prepared response. The FDA's postmarket reporting timelines are built into every engagement.
- Threat monitoring: We proactively monitor your device's ecosystem daily, with a named engineer triaging every match.
- Incident response: Response plans aligned with the FDA's postmarket timelines for uncontrolled risks (customer communication within 30 days, a fix within 60 days) - with audit-ready documentation from day one.
- Patch validation: Every patch goes through validation testing before deployment - so you can demonstrate to FDA that the fix didn't introduce new risk.
What lands in your eSTAR submission
Documents structured for the cybersecurity attachments of your submission - no reformatting on your side.
- TPLC Partnership: Annual retainer covering one product line through Total Product Lifecycle - SBOM monitoring, CISA-KEV tracking, full CVD process operation, quarterly penetration tests, and ongoing FDA/EU regulatory updates. One predictable fee, one accountable team, zero gaps between cleared release and end-of-support.
- SBOM monitoring: Section 524B requires manufacturers to maintain and update SBOMs continuously. We track every component for newly disclosed CVEs and flag them before they become reportable vulnerabilities.
- CVD program (Coordinated Vulnerability Disclosure): We manage the full CVD process - researcher intake, triage, fix timeline, and FDA notification - so your team doesn't face a public disclosure event without a prepared response. The FDA's postmarket reporting timelines are built into every engagement.
- Threat monitoring: We proactively monitor your device's ecosystem daily, with a named engineer triaging every match.
- Incident response: Response plans aligned with the FDA's postmarket timelines for uncontrolled risks (customer communication within 30 days, a fix within 60 days) - with audit-ready documentation from day one.
Standards that apply
The Infusion / Drug Delivery baseline, plus the call-outs that matter for fda postmarket cybersecurity in this segment.
Segment-specific call-outs
Section 524B + FDA postmarket cybersecurity guidance
We assess statutory applicability separately from guidance recommendations. The postmarket plan records monitoring, disclosure, and remediation procedures for the device in scope.
AAMI TIR97 + ISO/IEC 29147 and 30111
References for postmarket security risk management and coordinated vulnerability disclosure. The manufacturer retains clinical assessment, risk acceptance, and reporting decisions.
What's not in scope
We scope tightly on purpose. These items are either out-of-scope by design or belong in a separate engagement - we'll tell you up front, not after kickoff.
- Manufacturer risk acceptance, clinical decisions, or regulatory reporting decisions
- Automatic VEX conclusions without device-specific evidence and manufacturer approval
- Clinical validation or general software testing
- Firmware implementation or penetration testing unless separately scoped
FDA Postmarket Cybersecurity for Infusion / Drug Delivery - FAQs
The questions buyers in this segment actually ask before scoping a fda postmarket cybersecurity engagement.
Go deeper on Infusion / Drug Delivery and postmarket
A practical, ungated buyer's guide for medical device manufacturers evaluating cybersecurity partners, what goes wrong, why it costs you, and what to demand from your next engagement. Aligned to the FDA February 2026 premarket guidance.
A practical, ungated guide to the threat modeling gaps that trigger FDA cybersecurity questions in 510(k), De Novo, and PMA submissions - and exactly how to close them before reviewers find them.
The most common cybersecurity deficiencies in 510(k), De Novo, and PMA submissions, what triggers each one and how to fix it before you file. Aligned to the FDA February 2026 final guidance and Section 524B.
Medical device cybersecurity should scale with device risk. Christian Espinosa argues why meeting only the Section 524B minimum leaves patients and submissions exposed.
VEX resources for medical device teams: a document guide, SBOM comparison, and common assessment mistakes, with evidence-based status and regulatory context.
Medical device cybersecurity for nanotech neurostimulation: a fictional STRIDE threat model linking controller risks, patient harms, controls, and testing.
Other engagements for Infusion / Drug Delivery
Teams in this segment commonly bundle these alongside fda postmarket cybersecurity.
Keep going
Scope a FDA Postmarket Cybersecurity engagement for your infusion / drug delivery program.
A 30-minute discovery call with Christian Espinosa, Founder and CEO, and Kristy Kennedy, VP of Sales.